Quarterly ResultAug 6, 2026, 07:01 AM
Nuvation Bio Q2 Revenue Jumps to $31.69M; Net Loss $62.84M
AI Summary
Nuvation Bio reported a significant increase in total revenue for the second quarter of 2026, reaching $31.69 million, primarily driven by product revenue growth. Despite the revenue surge, the company's net loss widened to $(62.84) million. The company also issued $242.62 million in convertible debt and recognized a $9.47 million loss on debt extinguishment during the period.
Key Highlights
- Total revenue for Q2 2026 surged to $31.69 million from $4.83 million in Q2 2025.
- Product revenue for Q2 2026 increased to $23.19 million from $1.24 million in Q2 2025.
- Net loss for Q2 2026 was $(62.84) million, compared to $(59.01) million in Q2 2025.
- Cash and cash equivalents stood at $258.60 million as of June 30, 2026.
- Issued $242.62 million in convertible debt during the first half of 2026.
- Recognized a $9.47 million loss on debt extinguishment in Q2 2026.
- Warrant liability reduced to $0 as of June 30, 2026, as warrants expired.
- Accumulated deficit reached $(1.17) billion as of June 30, 2026.
Price Impact
More from NUVB